Covered recipient · General Payments record
CARL JACK FICHTENBAUM
Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$6,617.41
7 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $6,400.00 | 2 |
| Food and Beverage | $188.93 | 4 |
| Education | $28.48 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ViiV Healthcare Company | $3,900.00 | 1 |
| Theratechnologies Inc. | $2,513.96 | 2 |
| Gilead Sciences, Inc. | $174.97 | 3 |
| Janssen Pharmaceuticals, Inc | $28.48 | 1 |
Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CARL JACK FICHTENBAUM
NPI 1073578951 · CMS profile ID 2920
Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease
CINCINNATI, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1073578951?year=2022&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CARL JACK FICHTENBAUM, NPI 1073578951, CMS profile ID 2920. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073578951?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). CARL JACK FICHTENBAUM, NPI 1073578951, CMS profile ID 2920. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073578951?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- CARL JACK FICHTENBAUM, NPI 1073578951, CMS profile ID 2920, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1073578951?year=2022&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
7 matching records · $6,617.41 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–7 of 7.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | $29.75 | 10/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929509129 | CMS |
| Gilead Sciences, Inc. | $111.28 | 10/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929509137 | CMS |
| Gilead Sciences, Inc. | $33.94 | 08/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929509133 | CMS |
| Theratechnologies Inc. | $13.96 | 04/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943963841 | CMS |
| Theratechnologies Inc. | $2,500.00 | 04/12/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943963845 | CMS |
| ViiV Healthcare Company | $3,900.00 | 03/29/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944090853 | CMS |
| Janssen Pharmaceuticals, Inc | $28.48 | 01/18/2022 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886794325 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,213.04 | 4 |
| PY2025 | Principal investigator | $578,272.21 | 59 |
| PY2024 | Recipient | $473.50 | 2 |
| PY2024 | Principal investigator | $223,284.75 | 51 |
| PY2023 | Recipient | $1,149.35 | 11 |
| PY2023 | Principal investigator | $65,128.22 | 19 |
| PY2022 | Principal investigator | $109,613.44 | 27 |
| PY2021 | Recipient | $12,898.30 | 1 |
| PY2021 | Principal investigator | $167,018.23 | 49 |
| PY2020 | Principal investigator | $181,285.60 | 70 |
| PY2019 | Principal investigator | $263,157.10 | 91 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
91 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Gilead Sciences, Inc. | $862.00 | 12/18/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676398065 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,238.00 | 12/18/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676398069 |
| Principal investigator 1 | ViiV Healthcare Company | $1,000.00 | 12/18/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS CO | A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI | No dispute reported | 06/30/2026 | 709021889 |
| Principal investigator 1 | ViiV Healthcare Company | $390.00 | 12/17/2019 | Non-covered Recipient Entity UNIV OF CINCINNATI PHYSICIANS | A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI | No dispute reported | 06/30/2026 | 1021533231 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,039.00 | 11/20/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676398061 |
| Principal investigator 1 | ViiV Healthcare Company | $1,638.00 | 11/13/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS CO | PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ | No dispute reported | 06/30/2026 | 669629525 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $0.48 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691521989 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $40.80 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691522965 |
| Principal investigator 1 | Gilead Sciences, Inc. | $791.00 | 10/23/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676398047 |
| Principal investigator 1 | Gilead Sciences, Inc. | $809.00 | 10/23/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676398052 |
| Principal investigator 1 | Gilead Sciences, Inc. | $5,195.00 | 10/23/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676398057 |
| Principal investigator 1 | ViiV Healthcare Company | $1,640.00 | 10/23/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS CO | A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO | No dispute reported | 06/30/2026 | 669629915 |
| Principal investigator 1 | ViiV Healthcare Company | $7,139.34 | 10/22/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO | No dispute reported | 06/30/2026 | 669628927 |
| Principal investigator 1 | ViiV Healthcare Company | $2,927.79 | 10/22/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI | No dispute reported | 06/30/2026 | 669629083 |
| Principal investigator 1 | Gilead Sciences, Inc. | $425.00 | 10/21/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumaratein HIV and HBV Treatment Naive in Hepatitis B and HIV-1 Co-Infected Adults | No dispute reported | 06/30/2026 | 676398037 |
| Principal investigator 1 | Gilead Sciences, Inc. | $425.00 | 10/21/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676398041 |
| Principal investigator 1 | ViiV Healthcare Company | $300.00 | 10/17/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS CO | PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ | No dispute reported | 06/30/2026 | 669628823 |
| Principal investigator 1 | ViiV Healthcare Company | $1,250.00 | 10/17/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS CO | PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ | No dispute reported | 06/30/2026 | 669628825 |
| Principal investigator 1 | ViiV Healthcare Company | $1,500.00 | 10/17/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS CO | PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ | No dispute reported | 06/30/2026 | 669628827 |
| Principal investigator 1 | ViiV Healthcare Company | $390.00 | 10/17/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS CO | PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ | No dispute reported | 06/30/2026 | 669628829 |
| Principal investigator 1 | Gilead Sciences, Inc. | $425.00 | 10/16/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676398033 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $8,229.84 | 10/16/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691538401 |
| Principal investigator 1 | ViiV Healthcare Company | $13,432.12 | 10/11/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC | A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY | No dispute reported | 06/30/2026 | 669629223 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $38.40 | 10/08/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691519819 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1.28 | 10/08/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691521955 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $27.20 | 10/08/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691522271 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $27.20 | 10/08/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691522275 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $27.20 | 10/08/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691522279 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $3.48 | 10/08/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691522283 |
| Principal investigator 1 | Gilead Sciences, Inc. | $809.00 | 09/18/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676398027 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $18.00 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691458501 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,495.00 | 08/21/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676398023 |
| Principal investigator 1 | ViiV Healthcare Company | $3,252.60 | 08/14/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC | PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ | No dispute reported | 06/30/2026 | 669628045 |
| Principal investigator 1 | Amgen Inc. | $183.34 | 08/08/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | Ph3b Evolocumab in HIV Patients | No dispute reported | 06/30/2026 | 675795155 |
| Principal investigator 1 | ViiV Healthcare Company | $2,251.98 | 07/25/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI | No dispute reported | 06/30/2026 | 669627547 |
| Principal investigator 1 | ViiV Healthcare Company | $13,294.31 | 07/19/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC | A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY | No dispute reported | 06/30/2026 | 669627889 |
| Principal investigator 1 | ViiV Healthcare Company | $3,966.30 | 07/18/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO | No dispute reported | 06/30/2026 | 669628513 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,212.00 | 07/17/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676398009 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,530.00 | 07/17/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676398015 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,495.00 | 07/17/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676398019 |
| Principal investigator 1 | Amgen Inc. | $701.00 | 07/15/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | Ph3b Evolocumab in HIV Patients | No dispute reported | 06/30/2026 | 675778015 |
| Principal investigator 1 | ViiV Healthcare Company | $150.00 | 07/09/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI | No dispute reported | 06/30/2026 | 669627545 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,110.00 | 06/10/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC | A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor Combined With Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically-suppressed, Human Immunodeficiency Virus Type 1 Infected Subjects | No dispute reported | 06/30/2026 | 654263161 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $0.32 | 06/10/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691411713 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $38.40 | 06/10/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691414295 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $3.48 | 06/10/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691415415 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,117.00 | 05/22/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676398002 |
| Principal investigator 1 | ViiV Healthcare Company | $3,239.73 | 05/17/2019 | Non-covered Recipient Entity UC HEALTH | PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ | No dispute reported | 06/30/2026 | 669628043 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,425.00 | 05/15/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676397995 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,425.00 | 05/15/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676397999 |
| Principal investigator 1 | ViiV Healthcare Company | $1,300.00 | 05/09/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI | No dispute reported | 06/30/2026 | 669627837 |
| Principal investigator 1 | ViiV Healthcare Company | $7,986.42 | 05/01/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC | A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO | No dispute reported | 06/30/2026 | 669628515 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $4,800.74 | 04/29/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691456723 |
| Principal investigator 1 | ViiV Healthcare Company | $3,227.79 | 04/25/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI | No dispute reported | 06/30/2026 | 669626777 |
| Principal investigator 1 | ViiV Healthcare Company | $1,250.00 | 04/24/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC | A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY | No dispute reported | 06/30/2026 | 669627275 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,314.00 | 04/17/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676397979 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,867.00 | 04/17/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676397985 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,117.00 | 04/17/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676397989 |
| Principal investigator 1 | ViiV Healthcare Company | $17,326.39 | 04/15/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC | A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY | No dispute reported | 06/30/2026 | 669627273 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,057.46 | 04/03/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691456721 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,240.00 | 04/01/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676397973 |
| Principal investigator 1 | Amgen Inc. | $3,097.00 | 03/26/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | Ph3b Evolocumab in HIV Patients | No dispute reported | 06/30/2026 | 675795157 |
| Principal investigator 1 | ViiV Healthcare Company | $1,170.00 | 03/26/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI | No dispute reported | 06/30/2026 | 669626767 |
| Principal investigator 1 | ViiV Healthcare Company | $3,000.00 | 03/26/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC | A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI | No dispute reported | 06/30/2026 | 669627175 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 03/21/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | AN INTERNATIONAL MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY OF THE SAFETY OF MARAVIROC USED WITH OPTIMIZED BACKGROUND THERAPY IN TREATMENTEXPERIENCED HIV1 INFECTED PATIENTS | No dispute reported | 06/30/2026 | 671638991 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,867.00 | 03/20/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676397963 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,350.00 | 03/20/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676397969 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,082.12 | 03/19/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691294859 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $945.60 | 03/12/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691324741 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 03/04/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC | A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor Combined With Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically-suppressed, Human Immunodeficiency Virus Type 1 Infected Subjects | No dispute reported | 06/30/2026 | 654263159 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $945.60 | 02/28/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691324739 |
| Principal investigator 1 | Gilead Sciences, Inc. | $874.00 | 02/20/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676397945 |
| Principal investigator 1 | Gilead Sciences, Inc. | $921.00 | 02/20/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676397951 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,100.00 | 02/20/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen containing Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV 1 Infected Subjects who are Virologically Suppressed | No dispute reported | 06/30/2026 | 676397955 |
| Principal investigator 1 | Gilead Sciences, Inc. | $16,005.00 | 02/20/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676397959 |
| Principal investigator 1 | ViiV Healthcare Company | $2,633.67 | 02/15/2019 | Non-covered Recipient Entity UC HEALTH | PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ | No dispute reported | 06/30/2026 | 669626537 |
| Principal investigator 1 | Gilead Sciences, Inc. | $13,500.00 | 02/04/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676397939 |
| Principal investigator 1 | ViiV Healthcare Company | $390.00 | 02/01/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI | No dispute reported | 06/30/2026 | 669627173 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $780.00 | 01/31/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691311531 |
| Principal investigator 1 | Amgen Inc. | $10,013.76 | 01/28/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | Ph3b Evolocumab in HIV Patients | No dispute reported | 06/30/2026 | 675795159 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,455.00 | 01/28/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676397929 |
| Principal investigator 1 | Gilead Sciences, Inc. | $6,568.00 | 01/28/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects | No dispute reported | 06/30/2026 | 676397933 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $110.08 | 01/28/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH | A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects | No dispute reported | 06/30/2026 | 691415411 |
| Principal investigator 1 | Amgen Inc. | $24,264.00 | 01/26/2019 | Non-covered Recipient Entity UC HEALTHCARE SYSTEM UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY, LLC | Ph3b Evolocumab in HIV Patients | No dispute reported | 06/30/2026 | 675794796 |
| Principal investigator 1 | ViiV Healthcare Company | $6,346.08 | 01/22/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO | No dispute reported | 06/30/2026 | 669626491 |
| Principal investigator 1 | ViiV Healthcare Company | $1,951.98 | 01/17/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI | No dispute reported | 06/30/2026 | 669626769 |
| Principal investigator 1 | ViiV Healthcare Company | $9,145.82 | 01/17/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC | A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY | No dispute reported | 06/30/2026 | 669626967 |
| Principal investigator 1 | ViiV Healthcare Company | $250.00 | 01/17/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC | A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO | No dispute reported | 06/30/2026 | 669628485 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,100.00 | 01/09/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in HIV-1 Infected Adults on Chronic Hemodialysis | No dispute reported | 06/30/2026 | 676397923 |
| Principal investigator 1 | Gilead Sciences, Inc. | $425.00 | 01/03/2019 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults | No dispute reported | 06/30/2026 | 676397917 |
| Principal investigator 1 | ViiV Healthcare Company | $250.00 | 01/03/2019 | Non-covered Recipient Entity UC HEALTH | PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ | No dispute reported | 06/30/2026 | 669626535 |